Merck acuires Arqule: Non-covalent Btk kinase inhibitors take center stage
Merck (MRK.N) reported today that it is buying ARQL for over a 100% premium from Friday's closing price (https://reut.rs/341eQv1). This...
${alertText}
Want unlimited access? Try Pro free for 7 days.
Merck acuires Arqule: Non-covalent Btk kinase inhibitors take center stage
AMRN - Near-Term Price Acton Depends on Breadth of Label, but Acquisition Chatter and Quarterly Resu
ITCI - Investors Should Proceed with Caution with Imminent Phase 3 Readouts & FDA Decision In Co
Lots of Uncertainty in Upcoming GLYC Sickle Cell Readout
Big/Suspected Movers FAQ/User Guide
Quarterly Big Mover Biotech Stocks To Watch
Q2 2023 Product Revenue Analyses
BPIQ Q2 2023 Biotech Hedge Fund (13F) Analysis
SYFOVRE (APLS) vs. IZERVAY (Astellas)
BIIB & SAGE: Zuranolone
Apellis Pharmaceuticals (APLS)
Our platform helps you uncover your next biotech investment opportunity